IPX vaccine

The IPX vaccine is an individualized peptide-based immunotherapy developed by the University Hospital Tuebingen for the treatment of pediatric and young adult patients with metastatic fusion-driven sarcomas, specifically Ewing sarcoma, rhabdomyosarcoma, and synovial sarcoma. The vaccine is personalized for each patient, incorporating two primary peptide components: PERVI-NEO, which is derived from patient-specific nonsynonymous mutations identified via whole exome and RNA sequencing, and PERVI-FUS, which targets the unique fusion-breakpoint sequence characteristic of the patient's tumor. Additionally, a control peptide derived from Survivin is included. The vaccine is formulated with the novel Toll-like receptor (TLR) 1/2 ligand adjuvant XS15 and emulsified in Montanide ISA 51 VG to enhance the induction of tumor-specific T-cell responses. It is currently being evaluated in the Phase I/II PerVision clinical trial to assess safety and immunogenicity in patients who have achieved a clinical response following standard chemotherapy.

Other names

Individualized Peptide VaccinePerVision vaccine